Scientist – AAV Gene Therapy

Seattle, Washington State
Competitive Salary
January 27 2021
Position Type
Full Time
Organization Type

Scientist I – AAV Gene Therapy

The mission of the Allen Institute is to unlock the complexities of bioscience and advance our knowledge to improve human health. Using an open science, multi-scale, team-oriented approach, the Allen Institute focuses on accelerating foundational research, developing standards and models, and cultivating new ideas to make a broad, transformational impact on science.

We are seeking a scientist to join the gene therapy program at the Allen Institute for Brain Science.  This program aims to develop and test new therapeutic AAVs to treat brain disorders including severe forms of epilepsy and other neurodevelopmental diseases using a novel AAV-based cell type-specific expression system. We are seeking a scientist with a strong background in neuroscience, mouse models of neurological diseases, and molecular and cellular biology.

The scientist will lead efforts to build and validate new AAV-based therapeutics. These activities include developing AAVs that express transgenes in discrete brain cell types, and testing expression selectivity and biodistribution of reporters and therapeutic transgenes using qPCR, mFISH, and IHC. They will also be involved in testing efficacy of vectors for distinct disease indications. This individual must be excited by the prospect of joining a team-science environment at the Allen Institute for Brain Science to help develop new gene therapies for brain diseases.

The Allen Institute believes that team science significantly benefits from the participation of diverse voices, experiences and backgrounds. High-quality science can only be produced when it includes different perspectives. We are committed to increasing diversity across every team and encourage people from all backgrounds to apply for this role.

Essential Duties

  • Construction of AAV vectors using standard molecular techniques
  • Evaluation of expression in brain using IHC, mFISH, and fluorescence microscopy
  • Evaluation of biodistribution of AAV vectors
  • Phenotypic evaluation of animal model(s) of human neurological diseases, possibly including EEG
  • Become expert/point person on certain disease indications
  • Rapid and transparent communication of all successes and failures
  • Ability to take on complex problems and come up with novel solutions in a timeline, milestone-driven and team-centric environment
  • Presentation of results internally, externally and through publications
  • Interface with commercial partners to help coordinate efforts for vector development and testing